MedTrace Logo

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

NCT02549651 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2019-02-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 (durvalumab) alone and in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory dIffuse large B-cell lymphoma.

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

DRUG

MEDI4736

MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion

DRUG

tremelimumab

Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion

DRUG

AZD9150

AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • MedImmune LLC · MedImmune LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-13
Primary Completion
2019-02-04
Completion
2019-02-04
FDA Drug
Yes

Countries

  • United States
  • France
  • Ireland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02549651 on ClinicalTrials.gov